The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders

Muscle and Nerve

Volumn 20, Issue 2, 1997, Pages 136-147

  Van Der Meché, Frans G A ^a   Van Doorn, Pieter A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

chronic demyelinating polyneuropathies; Guillain Barre syndrome; immunoglobulins; myasthenia gravis; myositis

Indexed keywords

IMMUNOGLOBULIN G; PREDNISONE;

ALOPECIA; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DEMYELINATING NEUROPATHY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; EATON LAMBERT SYNDROME; FEVER; GUILLAIN BARRE SYNDROME; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; IMMUNOTHERAPY; MOTOR NEUROPATHY; MYALGIA; MYASTHENIA GRAVIS; MYOSITIS; PRIORITY JOURNAL; RASH; REVIEW;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; NEUROMUSCULAR DISEASES;

EID: 0031053185     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(199702)20:2<136::AID-MUS1>3.0.CO;2-D     Document Type: Review

References (16)

1. Ad Hoc Committee WHO-AIREN: Acute Onset Flaccid Paralysis. Genera, World Health Organization, 1993.
2. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force: Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991;41:617-618.
3. Amato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahenk Z, Kissel JT: Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1994;44:1516-1518.
4. Arakawa Y, Yoshimura M, Kobnyashi S, Ichihashi K, Miyao M, Momoi MY, Yanagisawa M: The use of intravenous immunoglobulin in Miller Fisher syndrome. Brain Dev 1993;15:231-233.
5. Arsura E: Experience with intravenous immunoglobulin in myasthenia gravis. Clin Immunol Immunopathol 1989;53:S170-S179.
6. Arsura EL, Bick A, Brunner NG, Namba T, Grob D: High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 1986;146:1365-1368.
7. Arsura EL, Bick A, Brunner NG, Grob D: Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci 1988;295:438-443.
8. Azulay J-P, Blin O, Pouget J, Boucraut J, Billé-Turc F, Carles G, Serratrice G: Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: A double-blind, placebo-controlled study. Neurology 1994;44:429-432.
9. Balzereit F, Fateh-Moghadam A, Besinger KA, Geursen RG: Myasthenia gravis: Humorale Diagnostik und Therapie einer Autoimmunkrankheit. Münchener Med Wochenschr 1986;128:654-657.
10. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR: Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course and recommendations for diagnostic criteria. Arch Neurol 1989;14:878-884.
11. Basta M, Dalakas MC: Mechanism of effectiveness of high-dose intravenous immunoglobulin (IVIg) in patients with dermatomyositis (DM): blockade of endomysial deposition of activated complement fragments. Neurology 1994;44(suppl 2):A346.
12. Bouche P, Moulonguet A, Younes-Chennoufi AB, Adams D, Baumann N, Meininger V, Léger J-M, Said G: Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry 1995;59:38-44.
13. Bouget J, Chevret S, Chastang C, Raphael JC, The French Cooperative Group: Plasma exchange morbidity in Guillain-Barré syndrome: results from the French prospective, double-blind, randomized, multicenter study. Crit Care Med 1993;21:651-658.
14. Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K: Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 1996;46:100-103.
15. Buckley RH, Schiff RI: The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991;325:110-117.
16. Castro LHM, Ropper AH: Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment. Neurology 1993;43:1034-1036.